[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Morax S, Desjardins L: [Orbital tumor emergencies in childhood]. J Fr Ophtalmol; 2009 May;32(5):357-67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In rare cases, they can be responsible for sudden, painful proptosis, due to orbital hemorrhage, with a risk of optic nerve compression, requiring emergency surgical treatment.
  • Neurogenous lesions, either isolated, such as in gliomas, or associated with a systemic disease, such as Recklinghausen neurofibromatosis, threaten the functional prognosis.
  • Biopsy is required in emergency situations, when rhabdomyosarcoma is suspected, in order to start the chemotherapy.
  • Treatment is closely related to the etiopathogenesis of the tumor.
  • They may require orbital surgery (biopsy, tumoral resection, orbital decompression in case of a compressive hemorrhage), systemic corticotherapy (as in immature adnexal hemangioma), radiation, and chemotherapy (rhabdomyosarcoma, secondary malignant tumor).
  • [MeSH-minor] Angiodysplasia / diagnosis. Angiodysplasia / therapy. Child. Emergencies. Humans. Lymphangioma / diagnosis. Lymphangioma / therapy. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19769875.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Hazarika P: Solitary malignant schwanoma of para pharyngeal space-a case report and review of literature. Indian J Otolaryngol Head Neck Surg; 2003 Oct;55(4):277-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignnant Schwannom is an aggressive tissue tumor that is more cnmitutnh found m assoiiatiun with Ion Recklinghausens disease.
  • The solitary tumors although rarer have a better prognosis when compared to those associated witk tan Recklinghausens disease.
  • The tase of a 16 year old girl with a parapharynccal malignant Schwnnaomu is presented Jor its rarity and our experience in dealing with it. .A combined modallty oftretument with surttery, radiotherapy and chemotherapy Was used.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1979 May;105(5):267-70 [435150.001]
  • [Cites] Laryngoscope. 1991 Oct;101(10):1044-9 [1921630.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Cancer. 1963 Aug;16:1003-14 [14050004.001]
  • [Cites] Ann Surg. 1970 Mar;171(3):419-28 [5416584.001]
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Ear Nose Throat J. 1988 Feb;67(2):103-7, 110 [3349955.001]
  • (PMID = 23120001.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451183
  • [Keywords] NOTNLM ; Malignant Schwannoma / Parapharyngeal Space Tumors
  •  go-up   go-down


3. Alimi KA, Firusian N, Dempke W: Effects of intralesional 32-P chromic phosphate in refractory patients with head and neck tumours. Anticancer Res; 2007 Jul-Aug;27(4C):2997-3000
Hazardous Substances Data Bank. CHROMIUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The clinical outcome of refractory head and neck (H&N) cancer patients remains poor despite novel treatment strategies.
  • PATIENTS AND METHODS: Fourteen patients (median age: 59 years) with either cytostatic drug-resistant tumours or tumours known to be primarily chemotherapy-resistant were entered into the study.
  • Eight patients exhibited a partial response, while 6 patients did not respond to the treatment.
  • Significant pathological and anatomical changes within the tumour tissue were demonstrated.
  • CONCLUSION: A lack of persistent systematic or local side-effects, as well as noteworthy efficacy, are properties of this novel regional treatment modality with 32-P chromic phosphate.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695485.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chromium Compounds; 0 / Phosphates; 0 / Radiopharmaceuticals; 28612-25-1 / chromic phosphate, 32P-labeled
  •  go-up   go-down


Advertisement
4. Schuppert F, Berger D, Peters H, Schröder S, Schöfl C, Tischler J, Hiller WF, von zur Mühlen A: [A young woman with neurofibromatosis 1 (Recklinghausen disease), abdominal tumor and hypertension]. Dtsch Med Wochenschr; 2000 Nov 17;125(46):1390-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A young woman with neurofibromatosis 1 (Recklinghausen disease), abdominal tumor and hypertension].
  • [Transliterated title] Eine junge Patientin mit Neurofibromatose Typ 1 (Morbus Recklinghausen), Unterbauchtumor und Hypertonus.
  • HISTORY AND ADMISSION FINDINGS: A 38-year-old woman, known to have type 1 neurofibromatosis (NF1; von Recklinghausen's disease) and recurrence of a malignant haemangiopericytoma in the lower abdomen developed hypertension.
  • Physical examination revealed tachycardia and paleness of the distal digits, in addition to multiple neurofibromas and café-au-lait spots.
  • TREATMENT AND COURSE: Because of the extensive local changes the recurrent haemangiopericytoma was only partially resected.
  • At the same time a right adrenalectomy was performed without complication.
  • Instead she was given weekly palliative chemotherapy with adriamycin, with little improvement.
  • [MeSH-minor] Adrenal Gland Neoplasms / diagnosis. Adult. Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Exons. Fatal Outcome. Female. Humans. Nerve Tissue Proteins / genetics. Neurofibromin 1. Palliative Care. Pheochromocytoma / diagnosis. Skin Neoplasms / diagnosis. Tachycardia

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11129996.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nerve Tissue Proteins; 0 / Neurofibromin 1; 80168379AG / Doxorubicin
  •  go-up   go-down


5. Brumariu O, Miron I, Munteanu M, Enache G, Stan G, Mihailiuc C, Dimov V, Dumitrescu G, Rusu C, Mihăilă D: [Association between phakomatosis and neoplasia in children pathology. IV Pediatric Clinic experience]. Rev Med Chir Soc Med Nat Iasi; 2000 Apr-Jun;104(2):143-9
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk to developing a neoplasm is increased when associated to a patient phakomatosis (Recklinghausen neurofibromatosis, Bourneville's tuberous sclerosis).
  • All cases had extensive and aggressive tumours at the moment of diagnosis, We noticed a poor response and an early relapse after chemotherapy.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12089980.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 20
  •  go-up   go-down


6. Kloke O: [Chemotherapy of non-small-cell bronchial carcinoma in elderly patients]. Z Gerontol Geriatr; 2001 Aug;34(4):277-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of non-small-cell bronchial carcinoma in elderly patients].
  • [Transliterated title] Chemotherapie des nichtkleinzelligen Bronchialkarzinoms bei älteren Patienten.
  • Results of large multicentric trials provide no evidence that elderly lung cancer patients who receive systemic chemotherapy have a worse outcome than younger patients.
  • There is, however, an underrepresentation of older patients in cancer treatment trials, at least in part due to the stringent eligibility criteria of these trials.
  • Recent studies specifically designed for elderly patients with advanced non-small-cell lung cancer have shown that chemotherapy improves survival and disease-related symptoms also in this age group.
  • However, the degree of comorbidity was found to affect both the tolerance to treatment and the survival outcome.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Female. Geriatric Assessment. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11584712.001).
  • [ISSN] 0948-6704
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Giesing M, Austrup F, Böckmann B, Driesel G, Eder C, Kusiak I, Suchy B, Uciechowski P, Grill HJ: Independent prognostication and therapy monitoring of breast cancer patients by DNA/RNA typing of minimal residual cancer cells. Int J Biol Markers; 2000 Jan-Mar;15(1):94-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostication and therapy monitoring of breast cancer patients by DNA/RNA typing of minimal residual cancer cells.
  • An analytical concept including a novel isolation procedure and a panel of tests for DNA and RNA typing of MRCCs is described and clinically evaluated in this paper.
  • The purification procedure exploiting the physical characteristics of MRCCs shows superior performance leading to > 50% pure and viable tumor cells.
  • On the basis of the proven presence of MRCCs tumor-relevant mRNAs can be adequately analyzed by normalized quantitative real-time RT-PCR.
  • The molecular characterization of MRCCs isolated from blood of breast cancer patients could have a strong clinical impact on prognostication, drug targeting and therapy monitoring.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10763149.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


8. Hoefert S, Eufinger H: Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct;110(4):463-9
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect of bisphosphonate (BP) medication.
  • STUDY DESIGN: We present 3 patients with renal cell carcinoma under BP medication who developed BRONJ during and after sunitinib medication.
  • The third patient showed relapse of completely healed BRONJ lesions shortly after resumption of a sunitinib therapy.
  • CONCLUSIONS: Oral mucositis during chemotherapy may raise the risk of BRONJ in cancer patients with BP medication.
  • Especially in renal cell carcinoma patients under sunitinib therapy and intravenous BP medication, oral mucositis should be observed closely because it could be a risk factor for BRONJ.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Renal Cell / drug therapy. Indoles / adverse effects. Kidney Neoplasms / drug therapy. Mandibular Diseases / chemically induced. Osteonecrosis / chemically induced. Pyrroles / adverse effects

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20692189.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / sunitinib; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


9. Kulka PJ, Toker H, Heim J, Joist A, Jakschik J: Suspected central anticholinergic syndrome in a 6-week-old infant. Anesth Analg; 2004 Nov;99(5):1376-8; table of contents
Hazardous Substances Data Bank. PHYSOSTIGMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He appeared to awaken after treatment with IV physostigmine in a dose of 0.04 mg/kg.
  • [MeSH-minor] Anesthesia, General. Arousal / drug effects. Herniorrhaphy. Humans. Infant. Infant, Newborn. Infant, Premature. Male. Physostigmine / adverse effects. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502033.001).
  • [ISSN] 0003-2999
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholinergic Antagonists; 9U1VM840SP / Physostigmine
  •  go-up   go-down


10. Höhler T, Staib L, Oettle H: [Treatment of advanced pancreatic carcinoma]. Onkologie; 2008;31 Suppl 5:29-31
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of advanced pancreatic carcinoma].
  • [Transliterated title] Therapie des fortgeschrittenen Pankreaskarzinoms.
  • Gemcitabine monotherapy extends survival times in locally advanced or metastatic pancreatic carcinoma compared with supportive treatment alone.
  • Among patients who develop skin lesions of grade 2 or more, giving erlotinib in addition doubles survival times - from 5.9 to 10.5 months.
  • Attempting therapy with gemcitabine plus erlotinib is therefore sensible.
  • In patients with a good performance status, survival times can be extended using the combinations gemcitabine plus capecitabine or gemcitabine plus platinum.
  • For second-line treatment, oxaliplatin, 5-FU, and folic acid can be used.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Deoxycytidine / analogs & derivatives. Palliative Care / methods. Pancreatic Neoplasms / drug therapy. Platinum / administration & dosage. Quinazolines / administration & dosage. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033702.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; 49DFR088MY / Platinum; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride
  • [Number-of-references] 8
  •  go-up   go-down


11. Malerba M, Garofalo A: [A rare case of nerve-sheath sarcoma with rhabdomyoblastic differentiation (malignant triton tumor)]. Tumori; 2003 Jul-Aug;89(4 Suppl):246-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant triton tumor (MTT) is a subtype of MPNST that also contain tissue with skeletal muscle differentiation (embryonal, plemorphic and botryoid rhabdomyosarcoma).
  • The estimated incidence of MPNSTs in patients with NF1 is 2-5% compared with 0.0001% in the general population and approximately 69% of the reported cases of MTT are associated with von Recklinghausen disease.
  • Seventeen months before, when the patient underwent surgery at the same Department for both a left-sided paravertebral inferior mediastinal neurofibroma and a right-sided axillary neurofibroma, diagnosis of von Recklinghausen disease (NF1) was made, according to the criteria established by the NIH Consensus Development.
  • The popliteal mass was resected too and resulted to be a neurofibroma just like the tumors resected 17 months before when diagnosis of von Recklinghausen disease was made.
  • Sarcoma arising in anatomic site other than extremity and superficial trunk are often more difficult to control because of anatomic constraints, delayed disease presentation, proximity to neurovascular and osseous structures and toxicity for normal adjacent tissues that limits the use of adequate radiation doses.
  • In contrast to the benefit most patients with high grade soft tissue sarcomas of the extremities receive from adjuvant radiation and chemotherapy, these modalities have been of little value for retroperitoneal tumors.
  • Current chemotherapy for retroperitoneal sarcomas is ineffective.
  • Local adjuvant therapy such as intraperitoneal chemotherapy or experimental immunotherapy seems to be attractive in theory, but needs further investigations through prospective randomized multicentric trials.
  • In conclusion, to date aggressive surgical management remains the most effective modality for selected primary and recurrent retroperitoneal soft tissue sarcomas including MPNSTs and the subtype MTT.
  • Patients with incomplete resection and other risk factors such as younger age and high grade tumors may be suitable candidates for investigational adjuvant therapy.
  • [MeSH-minor] Adult. Axilla. Cell Differentiation. Humans. Knee. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Muscles / pathology. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Spinal Nerve Roots / pathology. Spinal Nerve Roots / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12903608.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Böckmann B, Grill HJ, Giesing M: Molecular characterization of minimal residual cancer cells in patients with solid tumors. Biomol Eng; 2001 Mar;17(3):95-111
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The methods used are based on the detection of either genomic alterations in oncogenes and tumor suppressor genes or on the mRNA expression of tissue-specific and tumor-associated genes.
  • The additional implementation of techniques for cancer cell purification had a significant impact on analytical sensitivity and specificity of MRCC detection.
  • For patients with e.g. melanoma, breast, colorectal or prostate cancer it was demonstrated that the presence of disseminated cancer cells defines a subgroup of patients with reduced time to recurrence.
  • The possibility to use easily accessible body fluids as a source for MRCC detection enables longitudinal observations of the disease.
  • In this review we discuss the potential of molecular characterization of MRCC as a tool to improve prognostication, therapy selection and drug targeting as well as therapy monitoring.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11222984.001).
  • [ISSN] 1389-0344
  • [Journal-full-title] Biomolecular engineering
  • [ISO-abbreviation] Biomol. Eng.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A7851
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Number-of-references] 146
  •  go-up   go-down


13. Hoefert S, Eufinger H: [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. Mund Kiefer Gesichtschir; 2005 Jul;9(4):233-8
Hazardous Substances Data Bank. Alendronic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bisphosphonates are widely used in the treatment of cancer patients with hypercalcemia and bone metastases or in osteoporosis therapy.
  • Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates.
  • Official German drug committees have recently warned about the possibility of these side effects in the publication organs Deutsches Arzteblatt and Deutsche Apotheker Zeitung.
  • CASE REPORTS: So far we have had experience with seven patients showing therapy-resistant osteonecrosis of the mandible under bisphosphonate medication.
  • The presentation of these cases is intended to call attention to this clinically important side effect of bisphosphonate medication.
  • [MeSH-major] Alendronate / adverse effects. Diphosphonates / adverse effects. Imidazoles / adverse effects. Mandibular Diseases / chemically induced. Maxillary Diseases / chemically induced. Mouth Diseases / chemically induced. Osteonecrosis / chemically induced. Osteoporosis, Postmenopausal / drug therapy. Plasmacytoma / drug therapy

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Acad Med Singapore. 2004 Jul;33(4 Suppl):48-9 [15389307.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Sep;98(3):259-60 [15356460.001]
  • [Cites] J Orthop Res. 2004 May;22(3):465-71 [15099622.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Feb;32(1):10-5 [14729043.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4253-4 [14615459.001]
  • [Cites] J Clin Invest. 1999 Nov;104(10):1363-74 [10562298.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Dec;62(12):1563-5 [15573361.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Oct;61(10):1238-9 [14586868.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Sep;84(3):229-30 [9377182.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] Oncologist. 2004;9 Suppl 4:3-13 [15459425.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Jun;62(6):763-4 [15181903.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 17):11-6 [12520479.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1104-7 [12966490.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • [Cites] J Periodontol. 2003 Sep;74(9):1348-54 [14584869.001]
  • (PMID = 16395774.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; OYY3447OMC / pamidronate; X1J18R4W8P / Alendronate
  •  go-up   go-down


14. Baatz H, Mirshahi A, Puchta J, Gümbel H, Hattenbach LO: Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient. Ocul Immunol Inflamm; 2006 Jun;14(3):185-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient.
  • PURPOSE: To report a case of toxoplasma retinochoroiditis reactivation in an immunocompetent patient under atovaquone therapy.
  • Because earlier treatment regimens had either produced intolerable side effects and/or were deemed ineffective for the prevention of reactivation, the patient was started on atovaquone suspension (750 mg three times a day).
  • After initial regression of the lesion and still under atovaquone therapy, the patient presented again five weeks later with worsened best-corrected visual acuity.
  • CONCLUSIONS: To our knowledge, this is the first report of a reactivation of toxoplasma retinochoroiditis in an immunocompetent patient under atovaquone therapy, possibly indicating tachyzoite resistance to atovaquone.
  • [MeSH-major] Antiprotozoal Agents / therapeutic use. Chorioretinitis / parasitology. Immunocompetence. Naphthoquinones / therapeutic use. Toxoplasmosis, Ocular / parasitology
  • [MeSH-minor] Adult. Animals. Antibodies, Protozoan / analysis. Atovaquone. Drug Resistance, Microbial. Female. Humans. Oxidoreductases. Recurrence. Toxoplasma / immunology. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766403.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Protozoan; 0 / Antiprotozoal Agents; 0 / Naphthoquinones; EC 1.- / Oxidoreductases; Y883P1Z2LT / Atovaquone
  •  go-up   go-down


15. Hoefert S, Eufinger H: [Necrosis of the jaws under bisphosphonate therapy]. Orthopade; 2006 Feb;35(2):204, 206-9
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Necrosis of the jaws under bisphosphonate therapy].
  • Bisphosphonates are widely used in the treatment of cancer patients with hypercalcemia and bone metastases or in osteoporosis therapy.
  • Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates.
  • Official German drug committees have recently warned about the possibility of these side effects.
  • So far we have experience with 12 patients showing therapy-resistant osteonecrosis of the mandible under bisphosphonate medication, three of whom received oral bisphosphonates for osteoporosis treatment.
  • Presentation of these three cases provides more information on this clinically important side effect of oral bisphosphonate medication, also in osteoporosis therapy.
  • [MeSH-minor] Aged. Calcinosis / drug therapy. Female. Humans. Middle Aged. Osteoporosis / drug therapy

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344954.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopäde
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


16. Höhler T, Rüschoff J, Ridwelski K, Moehler M: [HER2 testing and targeted therapy in advanced gastric cancer]. Onkologie; 2010;33 Suppl 4:26-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HER2 testing and targeted therapy in advanced gastric cancer].
  • [Transliterated title] HER2-Diagnostik und zielgerichtete Therapie beim fortgeschrittenen Magenkarzinom.
  • Patients whose tumors were either scored on immunohistochemistry (IHC) as 3+ (independently of the result of fluorescence in situ hybridization (FISH)) or as IHC2+ and FISH+ were found, in a planned subgroup analysis, to have a median overall survival time of 16.0 months--versus 11.8 months when trastuzumab was not given.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Delivery Systems. Receptor, ErbB-2 / genetics. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Algorithms. Antibodies, Monoclonal, Humanized. Biopsy. Clinical Trials, Phase III as Topic. Drug Approval. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Multicenter Studies as Topic. Neoplasm Invasiveness. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Stomach / pathology. Survival Rate. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431310.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


17. Gong H, Zölzer F, von Recklinghausen G, Havers W, Schweigerer L: Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia; 2000 May;14(5):826-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • L-Asparaginase is used for the treatment of acute leukemias, but is sometimes ineffective or associated with severe side-effects.
  • Our results suggest the possibility of a future use of arginine deiminase for the therapy of leukemia.
  • [MeSH-major] Antineoplastic Agents / toxicity. Apoptosis / drug effects. Asparaginase / toxicity. Cell Cycle / drug effects. Cell Division / drug effects. Hydrolases / toxicity. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Child. HL-60 Cells. Humans. Jurkat Cells. Leukemia, B-Cell. Lymphocytes / drug effects. Lymphocytes / pathology. Mycoplasma / enzymology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10803513.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.- / Hydrolases; EC 3.5.1.1 / Asparaginase; EC 3.5.3.6 / arginine deiminase
  •  go-up   go-down


18. Mirshahi A, Schreyger F, Baatz H, Scharioth GB: [Macular translocation after photodynamic therapy: a case report]. Klin Monbl Augenheilkd; 2005 Jul;222(7):586-9
MedlinePlus Health Information. consumer health - Macular Degeneration.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Macular translocation after photodynamic therapy: a case report].
  • [Transliterated title] Makula-Translokation nach photodynamischer Therapie: ein Fallbericht.
  • BACKGROUND: Photodynamic therapy (PDT) and surgical macular translocation are concurrent treatment options for exudative age-related macular degeneration (ARMD).
  • We report a case of macular translocation with 360 degrees retinotomy after unsuccessful previous PDT for treatment of ARMD.
  • CONCLUSIONS: Macular translocation may be considered in cases of continuing deterioration after a previous PDT for treatment of exudative ARMD.
  • [MeSH-major] Hematoporphyrin Photoradiation. Macula Lutea / surgery. Macular Degeneration / drug therapy
  • [MeSH-minor] Aged. Choroidal Neovascularization / diagnosis. Choroidal Neovascularization / surgery. Combined Modality Therapy. Fluorescein Angiography. Follow-Up Studies. Humans. Male. Retina / surgery. Visual Acuity / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Klin Monbl Augenheilkd. 2005 Sep;222(9):747-8 [16231867.001]
  • (PMID = 16034727.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Siegert R, Gehanno P, Nikolaidis P, Bagger-Sjöbäck D, Ibanez JM, Hampel B, Sommerauer B: A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med; 2000 Apr;94(4):337-44
Hazardous Substances Data Bank. Cefuroxime axetil .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group.
  • The aim of this multicentre, randomized study was to compare the efficacy and safety of moxifloxacin (BAY 12-8039), a new 8-methoxy fluoroquinolone, with that of cefuroxime axetil for the treatment of acute bacterial sinusitis in adults.
  • The clinical success rate at the end of treatment in the evaluable population was significantly higher (96.7%) in the moxifloxacin group (204/211) than in the cefuroxime axetil group (204/225, 90.7%; 95% confidence intervals 1.5%; 10.6%).
  • Only one S. pneumoniae infection persisted following moxifloxacin therapy in contrast with three in individuals on cefuroxime axetil.
  • There were slightly more adverse events in the moxifloxacin group than in the cefuroxime axetil group, but there were fewer serious adverse events following moxifloxacin treatment (three vs. eight).
  • The drug was discontinued because of adverse events in 14 moxifloxacin patients and in 11 cefuroxime axetil patients.
  • Overall, in all assessments, moxifloxacin was at least as effective clinically and bacteriologically, and as well tolerated, as cefuroxime axetil in the treatment of acute sinusitis.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Aza Compounds. Bacterial Infections / drug therapy. Cefuroxime / analogs & derivatives. Cephalosporins / therapeutic use. Fluoroquinolones. Quinolines. Sinusitis / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Double-Blind Method. Drug Evaluation. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Sinusitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10845431.001).
  • [ISSN] 0954-6111
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Aza Compounds; 0 / Cephalosporins; 0 / Fluoroquinolones; 0 / Quinolines; 64544-07-6 / cefuroxime axetil; O1R9FJ93ED / Cefuroxime; U188XYD42P / moxifloxacin
  •  go-up   go-down


20. Siegert R, Berg O, Gehanno P, Leiberman A, Martinkenas JL, Nikolaidis P, Arvis P, Alefelder M, Reimnitz P: Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults. Eur Arch Otorhinolaryngol; 2003 Apr;260(4):186-94
Hazardous Substances Data Bank. Cefuroxime axetil .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults.
  • Among 452 patients considered valid for clinical efficacy, faropenem daloxate treatment was found to be statistically equivalent to cefuroxime axetil (89.0% vs. 88.4%-95% CI=-5.2%; +6.4%) at the 7-16 days post-therapy assessment.
  • At 28-35 days post-therapy, the continued clinical cure rate in the faropenem daloxate group was 92.6% and that for the cefuroxime axetil group was 94.9% (95% CI: -6.8%; +1.2%).
  • The bacteriological success rate at the 7-16 days post-therapy evaluation was similar in both treatment groups: 91.5% and 90.8% in the faropenem daloxate and cefuroxime axetil groups, respectively (95% CI=-9.2%; +9.5%).
  • At least one drug-related event was reported by 9.5% of the faropenem daloxate-treated patients and by 10.3% of those who received cefuroxime axetil.
  • The most frequently reported drug-related events were diarrhoea (2.2% versus 2.9%), nausea/vomiting (1.5% vs. 0.7%), abdominal pain (0.7% vs 1.5%) and skin reactions (1.5% vs. 1.1%).
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bacterial Infections / drug therapy. Cefuroxime / analogs & derivatives. Cefuroxime / therapeutic use. Lactams. Maxillary Sinusitis / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Double-Blind Method. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome. beta-Lactams

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12709801.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Lactams; 0 / beta-Lactams; 64544-07-6 / cefuroxime axetil; F52Y83BGH3 / fropenem; O1R9FJ93ED / Cefuroxime
  •  go-up   go-down






Advertisement